ロサルタンの世界市場

ロサルタンの世界市場は2030年までに17億米ドルに達する

2024年に15億米ドルと推定されるロサルタンの世界市場は、2030年には17億米ドルに達すると予測され、分析期間2024-2030年のCAGRは2.2%で成長すると予測されます。ロサルタンタブレットは、本レポートで分析したセグメントの1つであり、CAGRは1.9%を記録し、分析期間終了時には10億米ドルに達すると予測されます。ロサルタンPowder分野の成長率は分析期間中CAGR 2.6%と推定されます。

米国市場は4億1,230万米ドルと推定、中国はCAGR 4.3％で成長予測

米国のロサルタン市場は、2024年には4億1,230万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを4.3%として、2030年までに3億2,730万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8％と1.7％と予測されています。欧州では、ドイツがCAGR 1.2%で成長すると予測されています。

世界のロサルタン市場- 主要動向と促進要因のまとめ

ロサルタンが心血管系および腎臓治療の第一選択薬であり続ける理由とは？

アンジオテンシンII受容体拮抗薬（ARB）であるロサルタンは、その実証された有効性、良好な忍容性プロファイル、幅広い治療範囲により、世界の循環器および腎臓内科診療においてその地位を維持しています。もともとは高血圧症治療薬として開発されたが、現在では駆出率の低下した心不全、糖尿病性腎症、脳卒中予防などにも適応が広がっています。AT1受容体を選択的に阻害することにより、ロサルタンは血管収縮とアルドステロンの分泌を抑制し、ACE阻害剤によく見られる持続的な咳や電解質不均衡を起こすことなく血圧を下げます。この薬力学的優位性により、ロサルタンは、特にACE阻害薬に不耐容の患者において、多くの治療ガイドラインで好ましいARBとして位置づけられています。

また、高血圧、2型糖尿病、メタボリックシンドロームなど、心血管合併症のリスクを著しく上昇させる生活習慣病の世界の増加に伴い、ARBの重要性も高まっています。慢性腎臓病（CKD）患者において、ロサルタンは末期腎臓病の発症を遅らせるなど、血圧降下とは独立した腎保護効果を示しています。さらに、ヒドロクロロチアジドやアムロジピンとの併用療法は、複数の機序による血圧コントロールが必要な患者に対する標準的な治療法となっています。このような多面的な治療上の有用性と、ジェネリック医薬品としての幅広い入手可能性により、ロサルタンは世界のヘルスケアシステムにおいて高い臨床需要を維持しています。

製剤改良とジェネリックの普及は市場競争をどのように形成しているか？

ロサルタン市場は、特にCozaarやHyzaarといった先発品の特許切れに伴う激しいジェネリック競争が特徴です。これにより、特に中低所得国において、コストが大幅に低下し、入手しやすくなりました。現在では、数十社のメーカーがさまざまな用法・用量でロサルタンを製造しており、コモディティ化は進んでいるが、市場は拡大しています。このような環境下で差別化を図るため、製薬企業は製剤のイノベーション、製造効率、患者アドヒアランスの向上ソリューションに注力しています。

経口剤は依然として主流ですが、徐放性錠剤や口腔内崩壊錠の開発により、高齢者や嚥下障害のある患者向けの選択肢が広がっています。合剤も進化しており、複数の合併症を持つ患者の服薬コンプライアンスを最適化するための新しい組み合わせが考案されています。徐放性デリバリーシステムと1日1回投与レジメンは、慢性的な使用者のアドヒアランスを向上させるために優先されています。さらに、ARB供給における発がん性汚染物質に関する規制当局の監視を受け、ニトロソアミン不純物の低減を目指した製造技術革新により、工程管理が改善され、品質保証されたロサルタン製剤に対する規制当局の信頼が再び高まっています。こうした動向は、製品の安全性を強化すると同時に、競合市場においてブランドの差別化を支えています。

市場拡大において、臨床ガイドライン、疫学動向、アクセスプログラムが果たす役割とは？

ロサルタンが国際的な高血圧症管理ガイドラインや必須医薬品リストに掲載されていることは、市場でのシェアを維持する上で重要な要素です。WHO、米国心臓協会、欧州心臓病学会などの団体は、糖尿病患者や慢性腎臓病患者を含む高リスク集団の第一選択薬または第二選択薬としてARBを推奨し続けています。ARBは、心血管イベントを予防し、蛋白尿患者の腎機能低下を遅らせるという有用性から、特に高齢化社会や慢性疾患負担の高い患者において、集団健康管理における戦略的価値をさらに高めています。

疫学的動向も持続的な需要を支えています。高血圧症は世界で12億人以上が罹患しており、その多くが診断を受けていないか治療を受けていないです。糖尿病と肥満の世界の流行は、血圧降下と末端臓器保護の両方を提供するロサルタンのような心臓保護薬に対する需要を加速させています。公衆衛生機関や国際的なNGOによるアクセス・イニシアチブは、価格交渉、共同調達プログラム、医療保険の適用拡大を通じて、ロサルタンの入手可能性を高めています。こうした動きは、非感染性疾患が急増しているサハラ以南のアフリカ、東南アジア、ラテンアメリカで特に顕著であり、ロサルタンは低コストの治療レジメンにおいて極めて重要な役割を果たしています。

ロサルタン市場の長期的な成長と革新の原動力は？

ロサルタン市場の成長は、治療ニーズ、ヘルスケア政策、製薬戦略など、いくつかの交錯する動向によって牽引されています。その中でも特に、低所得層や高齢者層における心血管疾患や腎疾患の世界の負担の増加が挙げられます。政府や医療制度が非感染性疾患対策を優先する中、ロサルタンは臨床的有効性と経済的拡張性のバランスが取れた費用対効果の高いアンカー療法であり続けています。高血圧と糖尿病の大規模な集団検診プログラムは、診断患者を拡大し、ロサルタンの第一選択処方を増加させています。

さらに、統合ケアモデルと慢性疾患管理への動きは、ロサルタンが何年も、何十年も処方されるような持続的使用シナリオを生み出しています。ロサルタンと新規薬剤（SGLT2阻害剤やエンドセリン受容体拮抗剤など）を併用する製薬戦略は、進行した腎不全や心不全の症例に対して早期から検討されています。一方、サプライチェーン・モニタリングの改善、原薬のトレーサビリティ、AIを活用したファーマコビジランス・システムにより、特にジェネリック医薬品が支配的な市場において、世界・サプライチェーンにおける医薬品の品質保証が強化されつつあります。

さらに、この薬剤の良好なリスク・ベネフィット・レシオは、病院と地域社会の両方の環境での採用を促進し続けています。ロサルタンが単なる血圧コントロールにとどまらず、心血管の健康を守る役割を担っているという認識が高まっていることから、市場の見通しは引き続き堅調です。この安定性は、改良された製剤や合剤イノベーションによる製品ライフサイクルの最適化と相まって、ロサルタンが世界の医薬品業界において持続的な存在となるための位置づけとなっています。

セグメント

剤形（錠剤、粉末剤、懸濁剤）;用途（高血圧症用途、脳卒中用途、糖尿病性腎症用途、その他の用途）;流通チャネル（受託製造流通チャネル、自社製造流通チャネル、その他の流通チャネル）

調査対象企業の例（全48件）

• AdvaCare Pharma
• Aurobindo Pharma
• Cipla
• Dr. Reddy's Laboratories
• Healthy Life Pharma
• Hetero Labs
• Ipca Laboratories
• Jubilant Pharmova
• Lupin Limited
• Micro Labs
• Mylan（Viatris）
• Novartis
• Pfizer
• Solco Healthcare
• Sun Pharmaceutical Industries
• Teva Pharmaceuticals
• Torrent Pharmaceuticals
• Unichem Laboratories
• Zhejiang Hisun Pharmaceutical
• Zhejiang Tianyu Pharmaceutical

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Losartan Market to Reach US$1.7 Billion by 2030

The global market for Losartan estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Losartan Tablet, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the Losartan Powder segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$412.3 Million While China is Forecast to Grow at 4.3% CAGR

The Losartan market in the U.S. is estimated at US$412.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$327.3 Million by the year 2030 trailing a CAGR of 4.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Losartan Market - Key Trends & Drivers Summarized

Why Does Losartan Remain a First-Line Treatment in Cardiovascular and Renal Therapeutics?

Losartan, an angiotensin II receptor blocker (ARB), has retained its prominence in global cardiovascular and nephrology practices due to its proven efficacy, favorable tolerability profile, and broad therapeutic scope. Originally developed to manage hypertension, its indications have expanded to include heart failure with reduced ejection fraction, diabetic nephropathy, and stroke prevention. By selectively blocking the AT1 receptor, losartan inhibits vasoconstriction and aldosterone secretion, thereby reducing blood pressure without the persistent cough or electrolyte imbalances often associated with ACE inhibitors. This pharmacodynamic advantage has positioned losartan as the preferred ARB in many treatment guidelines, particularly in patients intolerant to ACE inhibitors.

Its relevance has grown in tandem with the global rise in lifestyle-related conditions such as hypertension, type 2 diabetes, and metabolic syndrome-each of which significantly elevates the risk of cardiovascular complications. In patients with chronic kidney disease (CKD), losartan has demonstrated renal-protective effects independent of blood pressure reduction, including delaying the onset of end-stage renal disease. Additionally, its use in combination therapies-often with hydrochlorothiazide or amlodipine-has become standard practice for patients requiring multi-mechanism blood pressure control. This multifaceted therapeutic utility, coupled with wide availability as a generic, has kept losartan in high clinical demand across global healthcare systems.

How Are Formulation Improvements and Generic Penetration Shaping Market Competition?

The losartan market is characterized by intense generic competition, especially following the patent expirations of branded versions such as Cozaar and Hyzaar. This has significantly driven down costs and improved accessibility, particularly in low- and middle-income countries. Dozens of manufacturers now produce losartan in various dosages and fixed-dose combinations, creating a highly commoditized but expansive market. To differentiate within this environment, pharmaceutical companies are focusing on formulation innovation, manufacturing efficiency, and improved patient adherence solutions.

Oral formulations remain dominant, but developments in extended-release tablets and orally disintegrating tablets are expanding options for elderly or dysphagic patients. Fixed-dose combinations are also evolving, with new pairings designed to optimize compliance in patients with multiple comorbidities. Sustained-release delivery systems and once-daily regimens are being prioritized to improve adherence among chronic users. Moreover, manufacturing innovations aimed at reducing nitrosamine impurities-following regulatory scrutiny over carcinogenic contaminants in ARB supplies-have led to improved process controls and renewed regulatory trust in quality-assured losartan formulations. These trends are reinforcing product safety while supporting brand differentiation in a competitive market.

What Role Do Clinical Guidelines, Epidemiological Trends, and Access Programs Play in Market Expansion?

The inclusion of losartan in international hypertension management guidelines and essential medicines lists is a critical factor in sustaining its market footprint. Organizations such as the WHO, American Heart Association, and European Society of Cardiology continue to recommend ARBs as first-line or second-line agents for high-risk populations, including diabetics and those with chronic kidney disease. The drug’s utility in preventing cardiovascular events and slowing renal function decline in proteinuric patients gives it additional strategic value in population health management, especially in aging societies and those with high chronic disease burdens.

Epidemiological trends also support sustained demand. Hypertension affects over 1.2 billion people globally, many of whom are undiagnosed or undertreated. The global prevalence of diabetes and obesity is accelerating demand for cardioprotective agents like losartan that offer both blood pressure reduction and end-organ protection. Access initiatives by public health agencies and international NGOs are increasing availability of losartan through price negotiations, pooled procurement programs, and health insurance coverage expansion. These dynamics are particularly pronounced in Sub-Saharan Africa, Southeast Asia, and Latin America, where non-communicable diseases are rising sharply and losartan plays a pivotal role in low-cost treatment regimens.

What Is Driving Long-Term Growth and Innovation in the Losartan Market?

The growth in the losartan market is driven by several intersecting trends across therapeutic need, healthcare policy, and pharmaceutical strategy. Chief among them is the rising global burden of cardiovascular and renal disorders, especially in low-income and aging populations. As governments and health systems prioritize non-communicable disease control, losartan remains a cost-effective anchor therapy that balances clinical efficacy with economic scalability. Large-scale population screening programs for hypertension and diabetes are expanding the pool of diagnosed patients, increasing first-line losartan prescriptions.

Additionally, the movement toward integrated care models and chronic disease management is creating sustained use scenarios where losartan is prescribed for years, even decades. Pharmaceutical strategies to combine losartan with novel agents-such as SGLT2 inhibitors or endothelin receptor antagonists-are under early exploration for advanced renal and heart failure cases. Meanwhile, improved supply chain monitoring, API traceability, and AI-enabled pharmacovigilance systems are strengthening drug quality assurance in global supply chains, particularly in generic-dominated markets.

Furthermore, the drug’s favorable risk-benefit ratio continues to drive adoption in both hospital and community settings. With growing awareness of losartan’s role in protecting cardiovascular health beyond mere blood pressure control, the market outlook remains strong. This stability, combined with product life cycle optimization through improved formulations and fixed-dose innovations, is positioning losartan for sustained relevance in the global pharmaceutical landscape.

SCOPE OF STUDY:

The report analyzes the Losartan market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Dosage Form (Tablet, Powder, Suspension); Application (Hypertension Application, Stroke Application, Diabetic Nephropathy Application, Other Applications); Distribution Channel (Contract Manufacturing Distribution Channel, In-house Manufacturing Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• AdvaCare Pharma
• Aurobindo Pharma
• Cipla
• Dr. Reddy's Laboratories
• Healthy Life Pharma
• Hetero Labs
• Ipca Laboratories
• Jubilant Pharmova
• Lupin Limited
• Micro Labs
• Mylan (Viatris)
• Novartis
• Pfizer
• Solco Healthcare
• Sun Pharmaceutical Industries
• Teva Pharmaceuticals
• Torrent Pharmaceuticals
• Unichem Laboratories
• Zhejiang Hisun Pharmaceutical
• Zhejiang Tianyu Pharmaceutical

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Losartan - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Hypertension and Cardiovascular Disorders Drives Demand for Losartan
  • Increased Use of ARBs in Multi-Drug Therapy Throws the Spotlight on Combination Formulations With Losartan
  • Patent Expiry and Generic Availability Expand Access and Market Penetration for Losartan Products
  • Integration of Losartan in Heart Failure and Diabetic Nephropathy Treatment Guidelines Strengthens Clinical Adoption
  • Growing Geriatric Population and Chronic Disease Burden Propel Demand for Long-Term Hypertension Therapy
  • Healthcare Cost Containment Policies in Emerging Economies Fuel Preference for Affordable Generic ARBs
  • Positive Real-World Evidence Supporting Renal Protective Benefits Enhances Clinical Trust in Losartan
  • Adoption in Multimorbidity Management Regimens Accelerates Prescriptions in Comorbid Patients
  • Regulatory Harmonization Across Regions Streamlines Approval and Market Expansion for Generic Losartan
  • Shift Toward Fixed-Dose Combinations Promotes Co-Packaged Formulations of Losartan With HCTZ
  • Growth in E-Prescription and Telehealth Channels Increases Accessibility of Losartan-Based Medications
  • Development of Extended-Release and Low-Dose Variants Supports Personalized Hypertension Management
  • Collaborations Between Manufacturers and Distribution Networks Improve Reach in Low-Income Markets
  • Increasing Focus on Drug Safety and Impurity Testing in ARBs Challenges Manufacturers on Compliance
  • Surge in Awareness of Blood Pressure Control Measures Strengthens Preventive Losartan Uptake
  • Formulary Inclusion in National Health Insurance Programs Expands Treatment Accessibility
  • Use in Off-Label Indications Such as Marfan Syndrome and Migraine Prevention Opens Niche Demand
  • High Substitution Rates by Pharmacists Sustain Losartan's Position in Cost-Sensitive Markets
  • Ongoing Price Pressures and Tender-Based Procurement Create Margin Challenges for Generic Suppliers
  • Continuous Education for General Practitioners Drives Primary Care Adoption of Losartan
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Losartan Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Losartan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Losartan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Losartan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Tablet by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Powder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Powder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Powder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Suspension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Contract Manufacturing Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Contract Manufacturing Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Contract Manufacturing Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for In-house Manufacturing Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for In-house Manufacturing Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for In-house Manufacturing Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hypertension Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hypertension Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hypertension Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Stroke Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Stroke Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Stroke Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Diabetic Nephropathy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Diabetic Nephropathy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Diabetic Nephropathy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• JAPAN
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• CHINA
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• EUROPE
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Losartan by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Losartan by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Losartan by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• FRANCE
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• GERMANY
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Losartan by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Losartan by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• INDIA
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Losartan by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Losartan by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Losartan by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Losartan by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Losartan by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Losartan by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
• AFRICA
  • Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION